- Two posters highlight Noltec Plus Tablets’ advanced formulation technology and superior pharmacokinetic profile
- Supect featured two posters detailing pharmacokinetic characteristics and correlations between drug exposure and key molecular response rates
[by Ji, Yong Jun] Il-yang Pharm announced on November 17 that it presented posters on the pharmacodynamic properties and clinical outcomes of Noltec Plus and Supect at ‘AAPS PharmSci 360,’ hosted by the American Association of Pharmaceutical Scientists (AAPS).
AAPS PharmSci 360, held from November 9 to 12 in San Antonio, Texas, USA, is an international academic conference and exhibition that showcases the latest research advancements and technological innovations in the pharmaceutical and biotechnology sectors. The event brings together global experts in pharmaceutical and biotechnology R&D, academic researchers, and industry professionals.
Il-yang Pharm presented two posters highlighting the advanced efficacy-enhancing formulation technology and pharmacodynamic characteristics of Noltec Plus, along with two additional posters detailing the clinical pharmacodynamic characteristics of Supect, Asia's first novel leukemia treatment. The supect-related presentations also included clinical findings on the correlation between drug exposure levels and key molecular response rates.
Noltec Plus tablets incorporate the latest sodium bicarbonate matrix formulation designed to accelerate the onset of action of conventional proton pump inhibitors (PPIs). This technology enables rapid absorption within one hour of administration without the need for an enteric coating. According to the company, nonclinical studies have demonstrated that this formulation delivers efficacy comparable to that of potassium-competitive acid blockers (P-CABs).
For Supect, one of the poster presentations reported results from a Phase 1 clinical trial led by Professor Lee Jang-ik of the College of Pharmacy at Seoul National University, as well as findings from a Phase 3 clinical study in Chinese patients with chronic myeloid leukemia. The analysis examined pharmacokinetic characteristics and explored the relationships among drug exposure levels, therapeutic response rates, and adverse reactions.